CGS-authored
At the heart of the debate over the use of CRISPR technology for gene-editing is the human embryo. While manipulation of the genomes of plants and animals also raises profound ethical issues, it is the possibility of altering the human genome which generates summits and white papers.
So this week, there was a flurry of activity about the ethics of human genetic engineering.
At the International Summit on Human Gene-Editing in Washington DC this week, convoked by the US science and medicine academies, the UK Royal Society and the Chinese Academy of Sciences, it was apparent that little had changed since 12-round fight over the use of human embryonic stem cells a decade ago. Even the characters had not changed much; some, like George Q. Daley, of Harvard, and Robin Lovell-Badge, from the UK, were leading defenders of human embryonic stem cell research.
The summit concluded that “It would be irresponsible to proceed with any clinical use of germline editing unless and until (i) the relevant safety and efficacy issues have been resolved … and (ii) there is...
.jpg){kind=link}